Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

• Status: Completed
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Orion Corporation, Orion Pharma

Criteria

Inclusion Criteria:

• Written informed consent

• Successful completion of study protocol 3104001

• Response or stable disease in study 3104001 at week 12

Exclusion Criteria:

• New serious concurrent medical condition

• Not able to swallow the study drug